Phase 1 Study of Two Merozoite Surface Protein 1 (MSP142) Vaccines for Plasmodium falciparum Malaria
2007

Study of Two Malaria Vaccines

Sample size: 60 publication 10 minutes Evidence: moderate

Author Information

Author(s): Malkin Elissa, Long Carole A, Stowers Anthony W, Zou Lanling, Singh Sanjay, MacDonald Nicholas J, Narum David L, Miles Aaron P, Orcutt Andrew C, Muratova Olga, Moretz Samuel E, Zhou Hong, Diouf Ababacar, Fay Michael, Tierney Eveline, Leese Philip, Mahanty Siddhartha, Miller Louis H, Saul Allan, Martin Laura B

Primary Institution: Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health

Hypothesis

The study aims to assess the safety and immunogenicity of two vaccines targeting Plasmodium falciparum malaria.

Conclusion

The MSP142/Alhydrogel vaccines were safe and well tolerated but not sufficiently immunogenic to generate a biologic effect in vitro.

Supporting Evidence

  • 74% of volunteers receiving MSP142-FVO/Alhydrogel developed antibodies.
  • 81% of volunteers receiving MSP142-3D7/Alhydrogel developed antibodies.
  • Antibodies were cross-reactive to both MSP142-FVO and MSP142-3D7 proteins.
  • Minimal in vitro growth inhibition of malaria parasites was observed.
  • Pain at the injection site was the most common side effect.
  • Majority of side effects were mild.
  • No serious adverse events were attributed to the vaccines.

Takeaway

The study tested two malaria vaccines on healthy volunteers and found they were safe but didn't work well enough to fight the disease.

Methodology

A Phase 1 open-label, dose-escalating study with 60 healthy volunteers receiving two different vaccines at three dose levels.

Potential Biases

The alternation method for assigning individuals to vaccines may introduce bias.

Limitations

The small number of participants and lack of a placebo arm limit the ability to detect differences in side effects.

Participant Demographics

60 healthy malaria-naïve volunteers aged 18-48, including 26 males and 34 females.

Statistical Information

P-Value

p<0.001

Confidence Interval

95% confidence interval: -19 to 13

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pctr.0020012

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication